Published in Eur J Immunol on September 01, 2000
Leukapheresis for Research on HCV-Coinfected Patients | NCT00076427
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science (2012) 3.39
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol (2001) 2.77
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol (2002) 2.26
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03
The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol (2003) 1.90
Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol (2002) 1.81
Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med (2004) 1.79
Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med (2005) 1.68
Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest (2006) 1.64
Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. J Clin Invest (2006) 1.59
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest (2004) 1.58
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med (2014) 1.51
Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut (2004) 1.42
Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol (2002) 1.40
Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut (2005) 1.33
Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol (2008) 1.28
High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol (2004) 1.25
Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol (2004) 1.25
Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J Virol (2004) 1.24
Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis (2012) 1.24
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol (2003) 1.23
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut (2005) 1.22
Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut (2006) 1.19
Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol (2010) 1.18
Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol (2007) 1.17
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success. Proc Natl Acad Sci U S A (2003) 1.15
Role of thymic output in regulating CD8 T-cell homeostasis during acute and chronic viral infection. J Virol (2005) 1.15
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses. J Virol (2004) 1.14
Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol (2008) 1.14
Managing occupational risks for hepatitis C transmission in the health care setting. Clin Microbiol Rev (2003) 1.13
Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol (2002) 1.05
Development of therapeutic HPV vaccines. Lancet Oncol (2009) 1.04
Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection. J Immunol (2012) 1.04
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol (2001) 1.02
Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat (2006) 1.00
Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection. Immunology (2007) 0.98
Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J (2007) 0.97
Dissection of antiviral and immune regulatory functions of tumor necrosis factor receptors in a chronic lymphocytic choriomeningitis virus infection. J Virol (2004) 0.95
Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology (2005) 0.95
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
T cells and pathogenesis of hantavirus cardiopulmonary syndrome and hemorrhagic fever with renal syndrome. Viruses (2011) 0.94
T cell sensitivity and the outcome of viral infection. Clin Exp Immunol (2009) 0.92
Differential effects of hepatitis C virus JFH1 on human myeloid and plasmacytoid dendritic cells. J Virol (2009) 0.92
Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies. J Virol (2002) 0.92
Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat (2008) 0.92
The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol (2011) 0.92
Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients. Mol Cells (2014) 0.91
HCV-HIV coinfection: simple messages from a complex disease. PLoS Med (2007) 0.91
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89
Viral escape mechanisms--escapology taught by viruses. Int J Exp Pathol (2001) 0.89
Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol (2002) 0.89
Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol (2015) 0.89
Indirect regulation of CD4 T-cell responses by tumor necrosis factor receptors in an acute viral infection. J Virol (2007) 0.89
Memory CD8+ T cell differentiation in viral infection: a cell for all seasons. World J Gastroenterol (2007) 0.87
Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology (2009) 0.87
Adaptive immune response during hepatitis C virus infection. World J Gastroenterol (2014) 0.85
Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol (2012) 0.85
Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine. J Clin Immunol (2005) 0.84
CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection. Front Immunol (2014) 0.83
Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Immunology (2014) 0.83
Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells. Clin Exp Immunol (2007) 0.82
Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver. Hum Vaccin (2011) 0.82
Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients. Open AIDS J (2008) 0.81
Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha. PLoS One (2007) 0.81
Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. J Immunol (2010) 0.80
A spatial view of the CD8+ T-cell response: the case of HCV. Rev Med Virol (2011) 0.79
Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses. Mol Ther (2013) 0.78
Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. J Gastroenterol Hepatol (2013) 0.78
Expression of hepatitis C virus core protein in hepatocytes does not modulate proliferation or apoptosis of CD8+ T cells. Yonsei Med J (2005) 0.77
Lack of variant specific CD8+ T-cell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C. Virol J (2013) 0.77
Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am (2015) 0.77
Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3. J Gen Virol (2011) 0.77
Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-alpha in patients with chronic hepatitis C. Croat Med J (2007) 0.77
A novel T cell evasion mechanism in persistent RNA virus infection. Trans Am Clin Climatol Assoc (2014) 0.77
Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss. Clin Exp Immunol (2005) 0.76
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
HLA-B alleles B*15:01 and B*15:02: opposite association with hepatitis C virus infection in Chinese voluntary blood donors. Intervirology (2015) 0.76
Apoptotic effects of a chimeric plant virus carrying a mimotope of the hepatitis C virus hypervariable region 1: role of caspases and endoplasmic reticulum-stress. J Clin Immunol (2012) 0.76
Cellular immune responses against persistent hepatitis C virus: gone but not forgotten. Gut (2006) 0.75
Timing of CD8 T cell effector responses in viral infections. R Soc Open Sci (2016) 0.75
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. PLoS Pathog (2017) 0.75
Hepatitis C Virus Stimulates Murine CD8α-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent Manner. PLoS Pathog (2016) 0.75
Clinical significance of the CCR5delta32 allele in hepatitis C. PLoS One (2014) 0.75
Adaptive immunity to hepatitis C virus. Viruses (2009) 0.75
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A (1997) 8.05
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Quantification of sleepiness: a new approach. Psychophysiology (1973) 6.36
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology (1999) 5.79
Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet (1995) 4.71
Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol (2001) 4.48
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 4.10
Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother (2005) 3.81
Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol (2001) 3.79
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis (2001) 3.68
Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature (1995) 3.61
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther (2011) 3.10
Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis (2000) 2.98
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest (1998) 2.97
Cardiac catheterisation by the Judkins technique as an outpatient procedure. BMJ (1989) 2.92
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med (1999) 2.76
Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut (2008) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 2.61
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
Oxygen-bridged dinuclear ruthenium amine complex specifically inhibits Ca2+ uptake into mitochondria in vitro and in situ in single cardiac myocytes. J Biol Chem (1998) 2.32
Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A (1999) 2.19
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
The role of glutamate dehydrogenase in plant nitrogen metabolism. Plant Physiol (1991) 2.15
Serum resistance among Escherichia coli strains causing urinary tract infection in relation to O type and the carriage of hemolysin, colicin, and antibiotic resistance determinants. Infect Immun (1982) 2.12
[21-year-old patient with recurrent diarrhea, weight loss, leg edema and iron deficiency. Gluten sensitive sprue]. Internist (Berl) (2002) 2.04
[Recurrence of unipolar depression and efficacy of maprotiline]. Encephale (1990) 2.04
Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology (2001) 1.99
Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A (2001) 1.99
Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol (1997) 1.98
Testing process errors and their harms and consequences reported from family medicine practices: a study of the American Academy of Family Physicians National Research Network. Qual Saf Health Care (2008) 1.98
Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator. EMBO J (1992) 1.96
Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 1.96
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines. J Virol (1992) 1.94
Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B. Mol Cell Biol (1996) 1.91
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol (2002) 1.81
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes. Am J Hum Genet (2001) 1.81
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet (1999) 1.79
Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet (1985) 1.75
Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc Natl Acad Sci U S A (2000) 1.72
Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology (1995) 1.72
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol (1995) 1.71
Necrotizing fasciitis due to Streptococcus pneumoniae after intramuscular injection of nonsteroidal anti-inflammatory drugs: report of 2 cases and review. Clin Infect Dis (2001) 1.69
Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol (1998) 1.67
Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo. Eur J Immunol (2000) 1.61
Posaconazole salvage treatment in paediatric patients: a multicentre survey. Eur J Clin Microbiol Infect Dis (2010) 1.60
Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol (2010) 1.60
Infective endocarditis: clinical spectrum, presentation and outcome. An analysis of 212 cases 1980-1995. Heart (2000) 1.58
Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology (1997) 1.58
Violence and injury mortality in the Cape Town metropole. S Afr Med J (1997) 1.55
Hepatitis B virus structure and biology. Microb Pathog (1989) 1.55
Altered gastric emptying in the head-injured patient: relationship to feeding intolerance. J Neurosurg (1991) 1.55
Labial fat pad grafts (modified Martius graft) in complex perianal fistulas. Ann R Coll Surg Engl (1998) 1.54
Congenital choledochal cyst: video-guided laparoscopic treatment. Surg Laparosc Endosc (1995) 1.54
Functional and phenotypic alterations in T cell subsets during the course of MAIDS, a murine retrovirus-induced immunodeficiency syndrome. J Immunol (1989) 1.53
Hepatitis B virus immunopathology. Springer Semin Immunopathol (1995) 1.52
A functional and kinetic comparison of antiviral effector and memory cytotoxic T lymphocyte populations in vivo and in vitro. Eur J Immunol (1997) 1.52
Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J (2001) 1.52
Differential antigen-processing pathways of the hepatitis B virus e and core proteins. Gastroenterology (1999) 1.52
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods (2004) 1.49
Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med (1991) 1.49
A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc Natl Acad Sci U S A (1999) 1.49
Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev (1997) 1.49
Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut (2009) 1.49
Descending necrotizing mediastinitis: surgical treatment via clamshell approach. Ann Thorac Surg (1996) 1.49
Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science (1995) 1.48
A method of reconstructing a natural-looking umbilicus in abdominoplasty. Ann Plast Surg (1997) 1.47
Exclusion of PTEN and 10q22-24 as the susceptibility locus for juvenile polyposis syndrome. Cancer Res (1997) 1.47
A cluster randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of classroom-based cognitive-behavioural therapy (CBT) in reducing symptoms of depression in high-risk adolescents. Health Technol Assess (2013) 1.46
Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol (1999) 1.46
Screening for prolonged incubation of HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis. BMJ (1990) 1.45
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol (2011) 1.45
Plasma thyrotropin response to thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders. J Clin Endocrinol Metab (1973) 1.44
An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. Trans R Soc Trop Med Hyg (2003) 1.44
Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem (1999) 1.44